ALFRESED 30 mg/5 ml Syrup

What is ALFRESED 30 mg/5 ml

ALFRESED is an oral liquid formulation containing Alimemazine (also known as trimeprazine tartrate), a first-generation phenothiazine derivative with antihistamine, sedative, and antiemetic properties. Each 5 ml dose delivers 30 mg of active drug, and it’s supplied in a 100 ml amber glass bottle, accompanied by an oral dosing syringe for accurate measurement.

• Generic Name: Alimemazine (trimeprazine)
• Form: Oral syrup/suspension
• Strength: 30 mg per 5 ml
• Packaging: 100 ml amber glass bottle + 5 ml syringe
• Pharmacological Class: First-generation antihistamine (H₁ antagonist) with sedative‑anticholinergic effects

ALFRESED is indicated for:

• Symptomatic relief of severe allergic manifestations (urticaria, pruritus)
• Short-term management of insomnia or agitation in adults and older children
• Adjunctive therapy in nausea/vomiting

Because of its sedative properties, ALFRESED is often used off-label in pediatric practice for sleep or restless conditions, but only under strict medical oversight due to potential behavioral and respiratory side effects.

How to use ALFRESED 30 mg/5 ml

ALFRESED syrup must be used carefully and according to medical instructions. Due to its sedative effect, dosing time and monitoring are crucial.

• Preparation:
  • Shake the bottle well before dosing to evenly distribute ingredients.
  • Use the provided syringe for exact measurement.
• Administration Guidelines:
  • Administer slowly, directly into the mouth, to ensure accurate dosage.
  • Can be given with water or juice if needed to improve taste.
• Timing: For sedation or sleep support, administer 30–60 minutes before bedtime.
• Duration: Use only for short periods (typically up to 7–10 days); longer use requires re-evaluation by a healthcare provider.
• Missed Dose: If a dose is missed, give it when remembered unless it’s near the time for the next dose—do not double doses.
• Monitoring: Observe for excessive drowsiness, respiratory changes, or paradoxical agitation, especially in pediatric or older adult populations.

Only use ALFRESED under medical supervision; self-prescribing for sleep or allergy relief is discouraged.

Mode of Action ALFRESED 30 mg/5 ml

Alimemazine, the active ingredient in ALFRESED, is a multi‑receptor blocking agent with the following pharmacological effects:

• H₁ Histamine Receptor Blockade: Prevents histamine binding in peripheral tissues, reducing itching, urticaria, and other allergic symptoms.
• CNS Depression and Sedation: Crosses the blood–brain barrier to antagonize H₁ receptors in the brain, causing drowsiness and calming effects.
• Anticholinergic Effects: Blocks muscarinic receptors, decreasing secretions, but potentially causing dry mouth and urinary retention.
• Anti-nausea/Antiemetic Action: May work by blocking central muscarinic and dopamine-2 receptors, reducing nausea and vomiting.

The overall pharmacodynamic profile makes ALFRESED effective for both allergic symptom relief and short-term sedation, although the anticholinergic activity can contribute to side effects such as dryness or urinary hesitation.

ALFRESED 30 mg/5 ml Interactions ALFRESED 30 mg/5 ml

Alimemazine may interact with various medications, especially those affecting the central nervous or cardiovascular systems. Important potential interactions include:

• CNS Depressants (e.g., benzodiazepines, opioids, alcohol): Additive sedation and respiratory depression may occur; combination should be avoided or closely monitored.
• Anticholinergic Medications (e.g., atropine, ipratropium): Combined use may intensify dry mouth, urinary retention, and constipation.
• MAO Inhibitors (e.g., phenelzine, tranylcypromine): May potentiate anticholinergic and sedative effects; use cautiously or avoid.
• Cardiac Agents (e.g., antiarrhythmics, amiodarone): Risk of QT prolongation; monitor ECG if co-administered.
• CYP450 Modulators: Alimemazine is metabolized in the liver via CYP pathways—inducers or inhibitors (e.g., ketoconazole, rifampicin) may alter drug levels.

Always disclose all medications (including OTC and supplements) to healthcare providers when using ALFRESED. Adjustments or increased monitoring may be needed.

Dosage of ALFRESED 30 mg/5 ml

Dosing differs by age, indication, and patient tolerance. Always follow physician directives and adjust dosage based on therapeutic effect and side effects.

• Adults:
  • Allergic conditions: 5–10 ml (30–60 mg) 3–4 times daily, adjusted for response.
  • Short-term sedation: 5–10 ml at bedtime.
• Adolescents (12–18 years): Similar to adult dosing, based on body weight and symptom severity.
• Children (2–12 years):
  • Allergy: 1–2 ml per year of age (up to 5 ml), 3–4 times daily.
  • Sedation: 1–2 ml/kg once at bedtime (typically 5–10 ml).
• Infants under 2 years: Use only under specialist supervision; very cautious dosing.
• Elderly: Start low (e.g., 5 ml at bedtime) to avoid over-sedation.

Maximum duration is usually 7–10 days; prolonged use must be supervised to minimize anticholinergic effects and sedation.

Possible side effects of ALFRESED 30 mg/5 ml

ALFRESED can cause various adverse reactions depending on dose and duration. Both common and rare side effects are important to recognize:

• Common:
  • Drowsiness, sedation
  • Dry mouth, nose, or throat
  • Mild dizziness
  • Gastrointestinal discomfort
• Less Common:
  • Constipation, urinary retention
  • Blurred vision
  • Headache, confusion (especially in elderly)
  • Hypotension or palpitations
• Rare or Serious:
  • Severe respiratory depression in overdose or with other CNS depressants
  • Cardiac arrhythmias (QT prolongation)
  • Agranulocytosis, blood dyscrasias
  • Allergic reactions (rash, swelling, anaphylaxis)

Monitor closely in vulnerable individuals (elderly, children, respiratory or cardiac illness). Discontinue and seek medical attention immediately if serious side effects occur.

ALFRESED 30 mg/5 ml Contraindications ALFRESED 30 mg/5 ml

ALFRESED should not be used in the following situations:

• Known hypersensitivity: Allergy to alimemazine or phenothiazines.
• Severe respiratory conditions: Sleep apnea, severe COPD—increased risk of sedation-related breathing issues.
• Comatose states: Due to risk of further CNS depression.
• Agranaulocytosis or severe bone marrow suppression: Potential hematologic worsening.
• Sensitive populations: Newborns, preterm infants, or children with immature respiratory drive.

Use with caution (with monitoring) in elderly, those with cardiac disease, urinary retention, glaucoma, or prostatic hypertrophy causing retention.

Storage of ALFRESED 30 mg/5 ml

Proper storage ensures efficacy and safety:

• Temperature: Store at controlled room temperature (15–25 °C / 59–77 °F). Avoid freezing.
• Light Protection: Keep the amber bottle tightly closed and away from direct sunlight.
• Childproofing: Keep out of reach/sight of children and secure the cap after use.
• Expiration: Discard after the printed expiry date; solution may degrade over time.
• Hygiene: Do not touch the syringe tip or leave the bottle open; avoid contamination.
• Disposal: Dispose of unused syrup and syringes per local pharmaceutical waste guidelines.

Proper storage maintains potency, prevents microbial growth, and protects against accidental ingestion.